Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection



Rating:

Share or cite this content

Citations should be made in the following way:
J. Wang (Taipei, Taiwan), H. Huang (Kaohsiung, Taiwan), J. Yang (Hsinchu, Taiwan), I. Chong (Kaohsiung, Taiwan). Late Breaking Abstract - Transcriptomic signature for precise prediction of systemic drug reaction during 3HP treatment for latent tuberculosis infection. 2478

Member's Comments

No comment yet.

Related content which might interest you: A combinatorial dual-immunoassay predicts reactivation risk for patients with previously incomplete treatment for latent tuberculosis infection Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016 Latent tuberculosis infection: a new paradigm Source: International Congress 2019 – State of the art session: Respiratory infections Year: 2019 Multiplexed cytokine and chemokine profiling in patients with latent tuberculosis infection: Treatment effect Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Utility of Th1-cell immune responses in differentiating active tuberculosis from latent tuberculosis infection Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Immune reactive profiling in subjects at risk of latent tuberculosis infection with TST(+)/IGRA(-) results. Source: International Congress 2018 – Tuberculosis transmission and screening strategies Year: 2018 Quantitative membrane proteomics reveals new functions ofCD13 in mycobacterium tuberculosis infection Source: International Congress 2015 – Biomarkers in TB: immunology and physiology Year: 2015 Biomarkers of systemic inflammatory response in patients with tuberculosis, combined with HIV infection Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016 Direct costs of three models for the screening of latent tuberculosis infection Source: Eur Respir J 2006; 28: 45-50 Year: 2006 Predictive factors of a delayed culture conversion under tuberculosis treatment Source: Annual Congress 2013 –Tuberculosis diagnosis Year: 2013 Utility of mycobacterium tuberculosis Rv0081-specific host gene expression to distinguish latent infection from active tuberculosis disease Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016 Evaluation of the accuracy of several immune experimental diagnostic tools to distinguish active tuberculosis from latent infection Source: International Congress 2015 – Science and biomarkers in TB Year: 2015 Treatment of latent tuberculosis infection: completion rates and adverse effects Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Latent tuberculosis infection in a drug treatment centre Source: Eur Respir J 2002; 20: Suppl. 38, 366s Year: 2002 Multiple cytokine response to mycobacterium tuberculosis with a whole blood assay is useful to distinguish active from latent tuberculosis infection in a highly tuberculosis endemic country Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 2 Year: 2014 Rapid detection of mycobacterial growth in in vitro cultures by VOC analysis Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Late Breaking Abstract - Correlation of sputum microRNA-144 expression levels with treatment response among pulmonary tuberculosis patients Source: International Congress 2018 – New developments in tuberculosis Year: 2018 Enhanced diagnosis of tuberculosis using a dual gene target detection approach Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR Year: 2016 Treatment of latent infection with Mycobacterium tuberculosis: update 2010 Source: Eur Respir J 2011; 37: 690-711 Year: 2011 Combined phenotypical and functional analysis of M. tuberculosis specific immunity for diagnosing active infection and risk assessment in latently infected individuals Source: International Congress 2014 – Future frontiers in the diagnosis of Mycobacterium tuberculosis infection Year: 2014 CD27 expression as a new tool to distinguish active tuberculosis from latent infection Source: International Congress 2015 – Science and biomarkers in TB Year: 2015